2149870307
Screenshot 2024-03-13 at 4.15.51 PM
Our Research
A Clinical Trial Report Of Autologous Bone Marrow‑derived Mesenchymal Stem Cell Transplantation In Patients With Spinal Cord Injury

Spinal cord injury (SCI) is a severe neurological disease. An effective strategy for the treatment of SCI is urgently required. Stem cell transplantation has emerged as a viable therapeutic option with great potential for restoring neurological function lost following SCI. From 2009 to 2010, a total of 20 SCI patients were enrolled in a clinical trial by Wuhan Hongqiao Brain Hospital; all patients completed and signed informed consent prior to autologous bone marrow-derived mesenchymal stem cell transplantation. Analysis of subsequent treatment results indicated significant improvements in sensory, motor and autonomic nerve func-tion as assessed by the American Spinal Injury Association’s impairment scale. Thirty days after transplantation, a total of 15 patients (75%) demonstrated improvement, including four of the eight patients (50%) with gradeA SCI, three of the four patients (75%) with gradeB injury and all eight patients (100%) with gradeC injury. The most common adverse events, fever and headache, disappeared within 24-48h without treatment.

PU-CHA JIANG, WEN-PING XIONG, GE WANG, CHAO MA, WEI-QI YAO, STEVENF.KENDELL, BRIAN M. MEHLING, XIAN-HOU YUAN and DONG-CHENG WU